Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (RNAC) Revenue
Annual & quarterly revenue history · segment & region breakdown
RNAC · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCartesian Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 92.81% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.04B | -92.81% |
| 2024-12-31 | $0.04B | +$0.01B | +49.64% |
| 2023-12-31 | $0.03B | -$0.08B | -76.53% |
| 2022-12-31 | $0.11B | +$0.03B | +30.21% |
| 2021-12-31 | $0.09B | +$0.07B | +412.60% |
| 2020-12-31 | $0.02B | +$0.01B | +148.57% |
| 2019-12-31 | $0.01B | +$0.01B | +639.42% |
| 2018-12-31 | $0.00B | +$0.00B | +336.23% |
| 2017-12-31 | $0.00B | -$0.01B | -97.44% |
| 2016-12-31 | $0.01B | +$0.00B | +34.47% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cartesian Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cartesian Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Cartesian Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RNAC revenue · 4 questionsRNAC's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 92.81% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Cartesian Therapeutics, Inc. SEC filings · GAAP · Cartesian Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026